Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the best assets.

Major pharmaceutical companies are pushing ahead with sweeping price increases on hundreds of medicines in the United States, ...

You’re reading The Financial Page, John Cassidy’s weekly column on economics and politics. It’s hard to find things that Donald Trump and Bernie Sanders agree on, but one point of consensus is that ...

For many Americans, pharmaceutical drugs are too expensive—and thanks to a system of complex and tedious bureaucracy, any effort for meaningful reform has been futile. Cost Plus Drugs wants to change ...

The pharma industry’s reputation has continued to slide — and it’s mostly due to the persistent issue of high drug costs, according to a report released by research firm PatientView this week.

The clock is ticking: In two weeks, millions of Americans could lose access to the affordable medication that’s helping them lose weight and improve their health. I should know — I’m one of them. In ...

Define Ventures’ new report provides a clear framework for how enterprise healthcare, particularly Big Pharma, is transitioning from AI exploration to execution. It focuses on core categories, ...

There’s probably no industry more reviled in the age of populism than Big Pharma. Both political parties now engage in knee-jerk demonization of one of the most successful and valuable sectors of the ...

Big Pharma recently announced a marketing campaign posing as patient advocacy. The industry’s trade association and advocacy arm said it is spending hundreds of billions of dollars to develop drugs ...

Pharmacy benefit managers, or PBMs, are crucial in helping employers like me negotiate with drug manufacturers, secure rebates, and pass down savings to keep costs manageable for businesses and ...